This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Azziz, R. Articles by Boots, L. R. Search for Related Content PubMed PubMed Citation Articles by Azziz, R. Articles by Boots, L. R.

Adrenal Androgen Excess in the Polycystic Ovary Syndrome: Sensitivity and Responsivity of the Hypothalamic-Pituitary-Adrenal Axis¹

Departments of Obstetrics and Gynecology (R.A., V.B., G.A.H., L.R.B.), Medicine (R.A.), and Biostatistics (L.M.F.), University of Alabama, Birmingham, Alabama 35233

Address all correspondence and requests for reprints to: Ricardo Azziz, M.D., M.P.H., Department of Obstetrics and Gynecology, University of Alabama, 618 South 20th Street, OHB 549, Birmingham, Alabama 35233-7333.

Over 50% of patients with the polycystic ovary syndrome (PCOS) demonstrate excess levels of adrenal androgens (AAs), particularly dehydroepiandrosterone sulfate (DHS). Nonetheless, the mechanism for the AA excess remains unclear. It has been noted that in PCOS the pituitary and ovarian responses to their respective trophic factors (i.e. GnRH and LH, respectively) are exaggerated. Similarly, we have postulated that excess AAs in PCOS arises from dysfunction of the hypothalamic-pituitary-adrenal axis, due to 1) exaggerated pituitary secretion of ACTH in response to hypothalamic CRH, 2) excess sensitivity/responsivity of AAs to ACTH stimulation, or 3) both. To test this hypothesis we studied 12 PCOS patients with AA excess (HI-DHS; DHS, >8.1 µmol/L or 3000 ng/mL), 12 PCOS patients without AA excess (LO-DHS; DHS, <7.5 µmol/L or 2750 ng/mL), and 11 controls (normal subjects). Each subject underwent an acute 90-min ovine CRH stimulation test (1 µg/kg) and an 8-h incremental iv stimulation with ACTH-(1–24) at doses ranging from 20–2880 ng/1.5 m²·h) with a final bolus of 0.25 mg. All patient groups had similar mean body mass indexes and ages, and both tests were performed in the morning during the follicular phase (days 3–10) of the same menstrual cycle, separated by 48–96 h. During the acute ovine CRH stimulation test, no significant differences in the net maximal response (i.e. change from baseline to peak level) for ACTH, dehydroepiandrosterone (DHA), androstenedione (A⁴), or cortisol (F) or for the DHA/ACTH, A⁴/ACTH, or F/ACTH ratios was observed. Nonetheless, the net response of DHA/F and the areas under the curve (AUCs) for DHA and DHA/F indicated a greater response for HI-DHS vs. LO-DHS or normal subjects. The AUC for A⁴ and A⁴/F and the A⁴/F ratio ( = net maximum change) indicated that HI-DHS and LO-DHS had similar responses, which were greater than that of the normal subjects, although the difference between LO-DHS patients and normal subjects reached significance only for the AUC of the A⁴ response. No difference in the sensitivity (i.e. threshold or minimal stimulatory dose) to ACTH was noted between the groups for any of the steroids measured. Nonetheless, the average dose of ACTH-(1–24) required for a threshold response was higher for DHA than for F and A⁴ in all groups. No difference in mean responsivity (slope of response to incremental ACTH stimulation) was observed for DHA and F between study groups, whereas the responsivity of A⁴ was higher in HI-DHS patients than in normal or LO-DHS women. The net maximal and the overall (i.e. AUC) responses of DHA were greater for HI-DHS than for normal or LO-DHS women. The response of A⁴ and the A⁴/F ratio were greater for HI-DHS patients than for LO-DHS patients or normal subjects. Alternatively, HI-DHS and LO-DHS patients had similar overall responses (i.e. AUC) for A⁴ or A⁴/F, although both were greater than those of normal subjects. The relative differences in response to incremental ACTH stimulation between steroids was consistent for all subject groups studied, i.e. A⁴ > F or DHA. In conclusion, our data suggest that AA excess in PCOS patients is related to an exaggerated secretory response of the adrenal cortex for DHA and A⁴, but not to an altered pituitary responsivity to CRH or to increased sensitivity of these AAs to ACTH stimulation. Whether the increased responsivity to ACTH for these steroids is secondary to increased zonae reticularis mass or to differences in P450c17 activity, particularly of the ⁴ pathway, remains to be determined.

This article has been cited by other articles:

				S. E Kasim-Karakas, W. M Cunningham, and A. Tsodikov Relation of nutrients and hormones in polycystic ovary syndrome Am. J. Clinical Nutrition, March 1, 2007; 85(3): 688 - 694. [Abstract] [Full Text] [PDF]

				E. CARMINA Ovarian and Adrenal Hyperandrogenism Ann. N.Y. Acad. Sci., December 1, 2006; 1092(1): 130 - 137. [Abstract] [Full Text] [PDF]

				R. Zhou, I. M. Bird, D. A. Dumesic, and D. H. Abbott Adrenal Hyperandrogenism Is Induced by Fetal Androgen Excess in a Rhesus Monkey Model of Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6630 - 6637. [Abstract] [Full Text] [PDF]

				E. Diamanti-Kandarakis and C. Piperi Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth Hum. Reprod. Update, November 1, 2005; 11(6): 631 - 643. [Abstract] [Full Text] [PDF]

				D.H. Abbott, D.K. Barnett, C.M. Bruns, and D.A. Dumesic Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum. Reprod. Update, July 1, 2005; 11(4): 357 - 374. [Abstract] [Full Text] [PDF]

				D. A. Ehrmann Polycystic Ovary Syndrome N. Engl. J. Med., March 24, 2005; 352(12): 1223 - 1236. [Full Text] [PDF]

				D. Glintborg, A. P. Hermann, K. Brusgaard, J. Hangaard, C. Hagen, and M. Andersen Significantly Higher Adrenocorticotropin-Stimulated Cortisol and 17-Hydroxyprogesterone Levels in 337 Consecutive, Premenopausal, Caucasian, Hirsute Patients Compared with Healthy Controls J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1347 - 1353. [Abstract] [Full Text] [PDF]

				B. O. Yildiz, K. S. Woods, F. Stanczyk, A. Bartolucci, and R. Azziz Stability of Adrenocortical Steroidogenesis over Time in Healthy Women and Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5558 - 5562. [Abstract] [Full Text] [PDF]

				T. Piltonen, R. Koivunen, A. Perheentupa, L. Morin-Papunen, A. Ruokonen, and J. S. Tapanainen Ovarian Age-Related Responsiveness to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3769 - 3775. [Abstract] [Full Text] [PDF]

				M. Guido, D. Romualdi, R. Suriano, M. Giuliani, B. Costantini, R. Apa, and A. Lanzone Effect of pioglitazone treatment on the adrenal androgen response to corticotrophin in obese patients with polycystic ovary syndrome Hum. Reprod., March 1, 2004; 19(3): 534 - 539. [Abstract] [Full Text] [PDF]

				M. Fassnacht, N. Schlenz, S. B. Schneider, S. A. Wudy, B. Allolio, and W. Arlt Beyond Adrenal and Ovarian Androgen Generation: Increased Peripheral 5{alpha}-Reductase Activity in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2760 - 2766. [Abstract] [Full Text] [PDF]

				D. Cermik, B. Selam, and H. S. Taylor Regulation of HOXA-10 Expression by Testosterone in Vitro and in the Endometrium of Patients with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., January 1, 2003; 88(1): 238 - 243. [Abstract] [Full Text] [PDF]

				A. P. Cheung, S. M. Pride, B. H. Yuen, and L. Sy In-vivo ovarian androgen responses to recombinant FSH with and without recombinant LH in polycystic ovarian syndrome Hum. Reprod., October 1, 2002; 17(10): 2540 - 2547. [Abstract] [Full Text] [PDF]

				S. A. Arslanian, V. Lewy, K. Danadian, and R. Saad Metformin Therapy in Obese Adolescents with Polycystic Ovary Syndrome and Impaired Glucose Tolerance: Amelioration of Exaggerated Adrenal Response to Adrenocorticotropin with Reduction of Insulinemia/Insulin Resistance J. Clin. Endocrinol. Metab., April 1, 2002; 87(4): 1555 - 1559. [Abstract] [Full Text] [PDF]

				G. Guercio, M. A. Rivarola, E. Chaler, M. Maceiras, and A. Belgorosky Relationship between the GH/IGF-I Axis, Insulin Sensitivity, and Adrenal Androgens in Normal Prepubertal and Pubertal Boys J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1162 - 1169. [Abstract] [Full Text] [PDF]

				R. Azziz, L. M. Fox, H. A. Zacur, C. R. Parker Jr., and L. R. Boots Adrenocortical Secretion of Dehydroepiandrosterone in Healthy Women: Highly Variable Response to Adrenocorticotropin J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2513 - 2517. [Abstract] [Full Text] [PDF]

				O. Barbier, C. Girard, L. Berger, M. El Alfy, A. Belanger, and D. W. Hum The Androgen-Conjugating Uridine Diphosphoglucuronosyltransferase-2B Enzymes Are Differentially Expressed Temporally and Spatially in the Monkey Follicle throughout the Menstrual Cycle Endocrinology, June 1, 2001; 142(6): 2499 - 2507. [Abstract] [Full Text] [PDF]

				J. W. M. Martens, D. H. Geller, W. Arlt, R. J. Auchus, V. S. Ossovskaya, H. Rodriguez, A. Dunaif, and W. L. Miller Enzymatic Activities of P450c17 Stably Expressed in Fibroblasts from Patients with the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4338 - 4346. [Abstract] [Full Text]

				R. Azziz, V. Y. Black, E. S. Knochenhauer, G. A. Hines, and L. R. Boots Ovulation After Glucocorticoid Suppression of Adrenal Androgens in the Polycystic Ovary Syndrome Is Not Predicted by the Basal Dehydroepiandrosterone Sulfate Level J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 946 - 950. [Abstract] [Full Text]